文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

晚期ALK阳性非小细胞肺癌患者脑转移管理的成本分析：阿来替尼与克唑替尼对比

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib.

作者信息

Isla Dolores, Massuti Bartomeu, Lázaro Martín, de Alda Lucía Ruiz, Gordo Rocio, Ortega-Joaquín Nuria, Oyagüez Itziar

机构信息

Medical Oncology Department, Lozano Blesa University Clinical Hospital, Zaragoza, Spain.

Medical Oncology Department, University General Hospital of Alicante, Alicante, Spain.

出版信息

Lung Cancer Manag. 2020 Mar 4;9(1):LMT28. doi: 10.2217/lmt-2019-0011.

DOI:10.2217/lmt-2019-0011
PMID:32256712
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7110588/
Abstract

AIM: To estimate management cost of NSCLC ALK+ patients with and without brain metastasis (BM), and to compare annual costs in patients treated with alectinib or crizotinib. METHODS: Management cost/year (€ 2018) in patients with and without BM was estimated with disaggregated resource consumption provided by local oncologists, including medical visits, hospitalizations, diagnostic/laboratory tests, imaging techniques and surgical procedures. The comparison of costs/year with alectinib and crizotinib, considered the cumulative 12-month incidence of BM in ALEX trial (9.4 and 41.4%, respectively). RESULTS: Management cost was €6173.42/patient-year without BM and €21,637.50/patient-year with BM. With alectinib, average cost/patient was lower than crizotinib (€4948.51/patient-year). CONCLUSION: Prevention of BM with alectinib may result in reductions of cost/year in the management of advanced ALK+ NSCLC.

摘要

目的：评估有和无脑转移（BM）的非小细胞肺癌（NSCLC）ALK阳性患者的管理成本，并比较接受阿来替尼或克唑替尼治疗患者的年度成本。 方法：根据当地肿瘤学家提供的分类资源消耗情况，估算有和无BM患者的年度管理成本（2018年欧元），包括医疗就诊、住院、诊断/实验室检查、成像技术和外科手术。阿来替尼和克唑替尼的年度成本比较，考虑了ALEX试验中BM的累积12个月发生率（分别为9.4%和41.4%）。 结果：无BM患者的管理成本为6173.42欧元/患者年，有BM患者为21637.50欧元/患者年。使用阿来替尼时，平均每位患者的成本低于克唑替尼（4948.51欧元/患者年）。 结论：使用阿来替尼预防BM可能会降低晚期ALK阳性NSCLC管理中的年度成本。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9bf/7110588/0b72656cff1f/lmt-09-28-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9bf/7110588/e9821db18697/lmt-09-28-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9bf/7110588/1a92ab7ebe91/lmt-09-28-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9bf/7110588/0b72656cff1f/lmt-09-28-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9bf/7110588/e9821db18697/lmt-09-28-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9bf/7110588/1a92ab7ebe91/lmt-09-28-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9bf/7110588/0b72656cff1f/lmt-09-28-g3.jpg

相似文献

[1]
Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib.

Lung Cancer Manag. 2020-3-4

[2]
Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer.

Lung Cancer. 2018-3-9

[3]
Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced -Positive NSCLC With or Without Baseline Central Nervous System Metastases.

JTO Clin Res Rep. 2023-2-24

[4]
Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.

J Med Econ. 2020-8

[5]
Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.

Lung Cancer. 2018-4-17

[6]
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.

Ann Oncol. 2018-11-1

[7]
Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced -Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study.

JTO Clin Res Rep. 2024-6-27

[8]
Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis.

Ann Palliat Med. 2020-7

[9]
Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China.

Adv Ther. 2019-3-21

[10]
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

N Engl J Med. 2017-6-6

引用本文的文献

[1]
Comparison of the effectiveness of alectinib versus crizotinib followed by alectinib in patients with ALK-positive advanced non-small-cell lung cancer in real-world setting and in the ALEX study.

Transl Lung Cancer Res. 2025-4-30

[2]
Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic LymphomakinasePositive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib.

Thorac Res Pract. 2023-7

[3]
Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain.

Glob Reg Health Technol Assess. 2022-9-12

本文引用的文献

[1]
Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France.

PLoS One. 2020-1-16

[2]
Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer.

Clin Drug Investig. 2020-2

[3]
Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer.

Cancer Manag Res. 2019-10-25

[4]
Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China.

Adv Ther. 2019-3-21

[5]
Economic burden of brain metastases in patients with non-small cell lung cancer: costs and implications.

Ann Palliat Med. 2019-4

[6]
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018).

Clin Transl Oncol. 2018-11-17

[7]
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2018-10-1

[8]
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

CA Cancer J Clin. 2018-9-12

[9]
Targeted Therapy for Patients With Metastatic Non-Small Cell Lung Cancer.

J Natl Compr Canc Netw. 2018-5

[10]
Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer.

Lung Cancer. 2018-3-9

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索